Antiviral Activity, Safety, and Exposure–Response relationships of GSK3532795, a Second-Generation HIV-1 Maturation Inhibitor, administered as Monotherapy or in Combination with Atazanavir±Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002).
Hwang, Carey, Schürmann, Dirk, Sobotha, Christian, Boffito, Marta, Sevinsky, Heather, Ray, Neelanjana, Ravindran, Palanikumar, Xiao, Hong, Keicher, Christian, Hüser, Andreas, Krystal, Mark, Dicker, IrLanguage:
english
Journal:
Clinical Infectious Diseases
DOI:
10.1093/cid/cix239
Date:
March, 2017
File:
PDF, 1.79 MB
english, 2017